24HourWire

24HourWire

News from all angles

MedPage Today Center

Novel Oral HAE Drug Measures Up to Injectable Options

(MedPage Today) -- Prophylactic use of the novel oral bradykinin B2 receptor antagonist deucrictibant substantially reduced hereditary angioedema (HAE) attacks, a pivotal phase III trial showed. For …

Redirecting to MedPage Today in 3 seconds...

Read Now → Explore 24HourWire

Share this story with your network